Timelapse viability assay to detect division and death of primary multiple myeloma cells in response to drug treatments with single cell resolution.

ABSTRACT: Heterogeneity among cancer cells and in the tumor microenvironment (TME) is thought to be a significant contributor to the heterogeneity of clinical therapy response observed between patients and can evolve over time. A primary example of this is multiple myeloma (MM), a generally incurable cancer where such heterogeneity contributes to the persistent evolution of drug resistance. However, there is a paucity of functional assays for studying this heterogeneity in patient samples or for assessing the influence of the patient TME on therapy response. Indeed, the population-averaged data provided by traditional drug response assays and the large number of cells required for screening remain significant hurdles to advancement. To address these hurdles, we developed a suite of accessible techno

SUBMITTER: Mark C 

PROVIDER: S-EPMC9175638 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature